Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2a

White, Carl W.; Sondheimer, Henry M.; Crouch, Edmond C.; Wilson, Harry; Fan, Leland L.

doi:10.1056/nejm198905043201807

Cited by 426 publications

(189 citation statements)

References 21 publications

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…Besides its antiviral activity, IFN-␣ downregulates the expression of VEGF in many human cancer cells 25,26 and inhibits endothelial cell migration in vitro 27 and in vivo. 28 IFN-␣ has been successfully used in patients with pulmonary hemangiomatosis, 29 angioblastomas, 30 and hemangioendotheliomas, 31 and has shown some degree of efficacy in HCC patients. 32,33 Therefore, the decrease in serum VEGF and Ang-2 levels in CHC patients could be related to the anti-angiogenic effects of IFN-␣.…”

Section: Discussionmentioning

confidence: 99%

The Potential of Angiogenesis Soluble Markers in Chronic Hepatitis C *

et al. 2005

View full text Add to dashboard Cite

Angiogenesis, the formation of new vessels, has been reported to play a significant pathogenic role in liver damage-associated hepatitis C virus infection. Most of our current knowledge derives from immunohistochemical studies of hepatic biopsy samples obtained from chronic hepatitis C (CHC) patients. We evaluated whether CHC is associated with elevated serum levels of angiogenesis markers and whether these are modulated by therapy. Vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang-2), and soluble Tie-2 (sTie-2) were determined in the serum of 36 CHC patients, before and after receiving antiviral combination therapy with pegylated interferon alpha-2b plus ribavirin, and in 15 healthy controls. CHC patients showed elevated baseline VEGF and Ang-2 levels. After treatment, both factors were decreased, whereas antiangiogenic sTie-2 was increased, indicating a shift toward an "anti-angiogenic" profile of serum markers in CHC patients. In conclusion, this suggests that serum VEGF, Ang-2, and sTie-2 levels could be useful as noninvasive, mechanistically based markers of response to therapy and disease progression in CHC. (HEPATOLOGY 2005;42: 696-701.)

show abstract

Section: Discussionmentioning

confidence: 99%

The Potential of Angiogenesis Soluble Markers in Chronic Hepatitis C *

et al. 2005

View full text Add to dashboard Cite

show abstract

“…6,10 Interferon a-2a has been suggested to be effective, although this has only been shown in in a few case reports. 3,10,18 Of note, prostacyclins such as epoprostenol, which are routinely used in the treatment of pulmonary hypertension, have been reported to have disastrous effects in patients with PCH. Several groups 2,3,10,12 have reported sudden- onset pulmonary edema and respiratory arrest after administration; thus, the use of these drugs is contraindicated.…”

Section: Differential Diagnosismentioning

confidence: 99%

Pulmonary Capillary Hemangiomatosis: A Rare Cause of Pulmonary Hypertension

O'Keefe

Post

2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Pulmonary capillary hemangiomatosis is a rare cause of pulmonary hypertension characterized by extensive proliferation of pulmonary capillaries within alveolar septae. Clinical presentation is nonspecific and includes dyspnea, cough, chest pain, and fatigue. Radiology shows diffuse centrilobular ground-glass opacities. Pulmonary capillary hemangiomatosis is clinically and radiographically indistinguishable from peripheral venoocclusive disease, making microscopic diagnosis essential. Histologically, pulmonary capillary hemangiomatosis shows an abnormal proliferation of small, thin-walled capillaries that expand the alveolar septae. The endothelial cells that comprise these lesions are cytologically bland and show no mitotic activity. Pulmonary capillary hemangiomatosis is important to recognize because prostacyclin therapy, a mainstay in the treatment of pulmonary hypertension, has been reported to cause sudden respiratory distress and death in these patients. Prognosis of this disease remains poor, and the only definitive treatment is lung transplantation.

show abstract

“…Also, several in vitro and in vivo studies (16)(17)(18)(19) have demonstrated an antiangiogenic activity attributed to IFN-ß in tumors. Chronic systemic administration of IFN-· or IFN-ß has been observed to produce regression of vascular tumors including Kaposi sarcoma (20), pulmonary hemangiomatosis (21), and hemangiomas (22); with only a marginal benefit for malignant gliomas (23). It has been reported that the combination of IFN with chemotherapy drugs increases the antitumor effects (24)(25)(26).…”

Section: Introductionmentioning

confidence: 99%

Potentiation of antiglioma effect with combined temozolomide and interferon-β

Park

Joe²,

Kim³

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

Abstract. Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity against high grade glioma. Interferon-ß (IFN-ß) is known to have antiproliferative and antiangiogenic activities. The aim of this study was to elucidate whether an antiglioma effect could be potentiated by the combination of TMZ and IFN-ß. In vitro, the combination of these drugs suppressed the proliferative and migratory activities, as well as enhance of the apoptosis and cell cycle (S phase) arrest of U-87 cells more efficiently than TMZ or IFN-ß alone. IFN-ß exerted a potent inhibitory effect on the proliferation of human umbilical vein endothelial cells (HUVEC); however, no additive or synergistic effect was observed with the addition of TMZ. To determine in vivo effect, nude mice bearing intracerebral U-87 xenograft inoculation were treated with intraperitoneal administration of PBS, TMZ (15 mg/kg for 3 days), IFN-ß (2x10 5 IU for 15 days), and a TMZ + IFN-ß combination. The combined treatment (median 62.0±8.6 days, P=0.0005) was observed to significantly increase the survival of the animals compared to treatment with PBS (median 30.0±2.5 days), TMZ (median 41.0±3.5 days) or IFN-ß (mean 36.0±2.5 days). These results suggest that antiglioma activity can be enhanced by the combination of TMZ and IFN-ß, providing the possibility for a new strategy development in the management of malignant glioma.

show abstract

Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2a

Cited by 426 publications

References 21 publications

The Potential of Angiogenesis Soluble Markers in Chronic Hepatitis C *

The Potential of Angiogenesis Soluble Markers in Chronic Hepatitis C *

Pulmonary Capillary Hemangiomatosis: A Rare Cause of Pulmonary Hypertension

Potentiation of antiglioma effect with combined temozolomide and interferon-β

Contact Info

Product

Resources

About